A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Condition: Non-Hodgkin Lymphoma Interventions: Drug: Epcoritamab; Drug: Lenalidomide; Drug: Ibrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride [HCl]; Drug: Prednisone; Drug: Polatuzumab Sponsors: AbbVie; Genmab Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Prednisone | Research | Revlimid | Rituxan | Study